Amplification of erbB2 and erbB2 expression are superior to estrogen receptor status as risk factors for distant recurrence in pT1N0M0 breast cancer: a nationwide population-based study
- PMID: 12631589
Amplification of erbB2 and erbB2 expression are superior to estrogen receptor status as risk factors for distant recurrence in pT1N0M0 breast cancer: a nationwide population-based study
Abstract
Purpose: To assess the relative importance of 10 prognostic factors in pT1N0M0 breast cancer (< or =2 cm in diameter, node negative).
Experimental design: Women diagnosed with breast cancer in Finland from 1991 to 1992 were identified from the files of the Finnish Cancer Registry, and individual clinicopathological data were collected from the hospital case records of women living in five regions comprising about one-half of the Finnish population. Of the women with minimum required information available (n = 2842), 852 had unilateral pT(1)N(0)M(0) cancer. The median follow-up time was 9.5 years, and only 5% had received systemic adjuvant therapy. Estrogen receptor (ER), progesterone receptor, erbB2, p53, and Ki-67 expression was determined from tumor tissue microarrays using immunohistochemistry, and the erbB2 (HER-2) amplification status was determined using chromogenic in situ hybridization.
Results: Primary tumor size < or =5 mm and histological grade 1 were associated with 100 and 95% (95% confidence interval, 92-98%) 9-year distant disease-free survival, respectively, whereas strong erbB2 expression or the presence of >20% Ki-67-positive cells was associated with >20% risk. ER and progesterone receptor values obtained from the hospital case records or tumor microarrays showed weaker association with outcome than the erbB2 status. Small (< or =10 mm) erbB2-negative cancers were associated with >90% 9-year distant disease-free survival, irrespective of histological grade.
Conclusions: Prognosis of pT(1)N(0)M(0) breast cancer is generally well defined by the histological grade and primary tumor size. The erbB2 status was superior to ER as a prognostic factor in these tumors.
Similar articles
-
Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.BMC Cancer. 2007 Apr 12;7:63. doi: 10.1186/1471-2407-7-63. BMC Cancer. 2007. PMID: 17430582 Free PMC article.
-
Prognostic role of a multigene reverse transcriptase-PCR assay in patients with node-negative breast cancer not receiving adjuvant systemic therapy.Clin Cancer Res. 2005 May 1;11(9):3315-9. doi: 10.1158/1078-0432.CCR-04-1707. Clin Cancer Res. 2005. PMID: 15867229
-
Relationship between c-erbB-2 and other tumor characteristics in breast cancer prognosis.Clin Cancer Res. 2000 Dec;6(12):4745-54. Clin Cancer Res. 2000. PMID: 11156229
-
Prognostic and predictive factors in breast cancer.Cancer Treat Rev. 2001 Jun;27(3):137-42. doi: 10.1053/ctrv.2000.0207. Cancer Treat Rev. 2001. PMID: 11417963 Review.
-
[Prognostic factors for breast cancer].Gan To Kagaku Ryoho. 1995 Aug;22(9):1279-84. Gan To Kagaku Ryoho. 1995. PMID: 7661581 Review. Japanese.
Cited by
-
Prediction of Cardiac Toxicity by Measurement of Coronary Artery Calcium Scoring Method Using Chest Computed Tomography in Early Breast Cancer Patients Treated with Trastuzumab.Breast Care (Basel). 2023 Feb;18(1):22-30. doi: 10.1159/000527683. Epub 2022 Nov 3. Breast Care (Basel). 2023. PMID: 36876165 Free PMC article.
-
Long-Term Survival Outcomes of Patients with Small (≤1 cm) Node-Negative HER2-Positive Breast Cancer Not Treated with Adjuvant Anti-HER2-Targeted Therapy: A 10-Year Follow-Up Study.Breast Care (Basel). 2022 Jun;17(3):279-287. doi: 10.1159/000520793. Epub 2021 Nov 9. Breast Care (Basel). 2022. PMID: 35957947 Free PMC article.
-
Outcome and Biomarker Supervised Deep Learning for Survival Prediction in Two Multicenter Breast Cancer Series.J Pathol Inform. 2022 Jan 18;13:9. doi: 10.4103/jpi.jpi_29_21. eCollection 2022. J Pathol Inform. 2022. PMID: 35136676 Free PMC article.
-
Characteristics and clinical outcome of pT1a-b node-negative breast cancer.North Clin Istanb. 2021 Mar 24;8(2):124-129. doi: 10.14744/nci.2020.06332. eCollection 2021. North Clin Istanb. 2021. PMID: 33851075 Free PMC article.
-
Approaching Neoadjuvant Therapy in the Management of Early-Stage Breast Cancer.Breast Cancer (Dove Med Press). 2021 Mar 30;13:199-211. doi: 10.2147/BCTT.S273058. eCollection 2021. Breast Cancer (Dove Med Press). 2021. PMID: 33833568 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical
Research Materials
Miscellaneous